Mustang Bio (MBIO) Projected to Announce Earnings on Wednesday

Mustang Bio (NASDAQ:MBIO) is expected to announce its Q3 2026 results on Wednesday, November 18th. Analysts expect the company to post earnings of ($140.00) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 7:00 AM ET.

Mustang Bio (NASDAQ:MBIO) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($140.00) by $139.86.

Mustang Bio Price Performance

NASDAQ:MBIO opened at $0.45 on Wednesday. The firm has a market capitalization of $3.41 million, a price-to-earnings ratio of -1.00 and a beta of 2.19. Mustang Bio has a one year low of $0.35 and a one year high of $1.43. The business has a fifty day moving average price of $0.45 and a 200-day moving average price of $0.67.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Mustang Bio in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Mustang Bio Company Profile

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases, including cancer and rare genetic disorders. The company’s work centers on engineered immune-cell therapies designed to recognize and attack cancer cells, as well as gene therapies intended to address underlying disease causes. Mustang’s development programs have included CAR T-cell therapies for hematologic malignancies and solid tumors. Its pipeline has featured MB-106, an investigational CD20-targeted CAR T-cell therapy for certain B-cell cancers, and programs targeting glioblastoma and other difficult-to-treat cancers.